RESUMEN
Trazodone is a serotonin receptor antagonist and reuptake inhibitor used extensively as an anxiolytic in human and small animal veterinary medicine. The aims of this study were to determine the pharmacokinetics of oral trazodone in experimental horses and to evaluate the effect of oral trazodone in clinical horses. Six experimental horses were administered trazodone at 7.5 or 10 mg/kg. Plasma concentrations of trazodone and its metabolite (m-CPP) were determined via UPLC-MS/MS. Noncompartmental pharmacokinetic analysis, sedation and ataxia scores were determined. Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 µg/ml and half-life of the terminal phase of approximately 7 hr. The metabolite was present at low levels in all horses, representing only 2.5% of the total area under the curve. In experimental horses, concentration-dependent sedation and ataxia were noted, lasting up to 12 hr. For clinical cases, medical records of horses treated with trazodone for various abnormal behaviours were reviewed and data were summarized. Trazodone was successful in modifying behavioural problems to some degree in 17 of 18 clinical cases. Tolerance and subsequent lack of drug effect occurred in two of 18 clinical cases following 14 or 21 days of use. In both populations of horses, adverse effects attributed to trazodone include oversedation, muscle fasciculations and transient arrhythmias.
Asunto(s)
Ansiolíticos/farmacocinética , Caballos/sangre , Piperazinas/farmacocinética , Agonistas de Receptores de Serotonina/farmacocinética , Trazodona/farmacocinética , Administración Oral , Animales , Ansiolíticos/administración & dosificación , Ansiolíticos/farmacología , Área Bajo la Curva , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Semivida , Masculino , Piperazinas/administración & dosificación , Piperazinas/farmacología , Agonistas de Receptores de Serotonina/administración & dosificación , Agonistas de Receptores de Serotonina/farmacología , Trazodona/administración & dosificación , Trazodona/farmacologíaAsunto(s)
Cannabinoides/uso terapéutico , Marihuana Medicinal/uso terapéutico , Neoplasias/terapia , Cuidados Paliativos/métodos , Dolor en Cáncer/prevención & control , Ensayos Clínicos como Asunto , Femenino , Humanos , Náusea/inducido químicamente , Náusea/prevención & control , Ensayos Clínicos Controlados Aleatorios como Asunto , Vómitos/inducido químicamente , Vómitos/prevención & controlRESUMEN
As a result of the Leadership Conference on Biomedical Research and the Environment, the Facilities Committee focused its work on the development of best environmental practices at biomedical research facilities at the university and independent research facility level as well as consideration of potential involvement of for-profit companies and government agencies. The designation "facilities" includes all related buildings and grounds, "green auditing" of buildings and programs, purchasing of furnishings and sources, energy efficiency, and engineering services (lighting, heating, air conditioning), among other activities. The committee made a number of recommendations, including development of a national council for environmental stewardship in biomedical research, development of a system of green auditing of such research facilities, and creation of programs for sustainable building and use. In addition, the committee recommended extension of education and training programs for environmental stewardship, in cooperation with facilities managers, for all research administrators and researchers. These programs would focus especially on graduate fellows and other students, as well as on science labs at levels K--12.